Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arch Biopartners Inc (ARCH.VN)

Arch Biopartners Inc (ARCH.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 107,908
  • Shares Outstanding, K 63,851
  • Annual Sales, $ 0 K
  • Annual Income, $ -3,327 K
  • 60-Month Beta 2.16
  • Price/Sales N/A
  • Price/Cash Flow 10,053.24
  • Price/Book N/A
Trade ARCH.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.03
  • Most Recent Earnings $-0.02 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend 0.200 on 09/13/00
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.620 +4.32%
on 06/06/24
1.790 -5.59%
on 06/10/24
-0.040 (-2.31%)
since 05/14/24
3-Month
1.560 +8.33%
on 04/30/24
2.560 -33.98%
on 03/18/24
-0.310 (-15.50%)
since 03/14/24
52-Week
0.970 +74.23%
on 11/03/23
2.560 -33.98%
on 03/18/24
-0.260 (-13.33%)
since 06/14/23

Most Recent Stories

More News
U.S. Eases into Memorial Day Weekend

Monday U.S. Markets are Closed for Memorial Day Tuesday U.S. Economic Lookahead S&P ...

ARCH.VN : 1.690 (-1.17%)
DAC.VN : 0.005 (unch)
EGT.VN : 0.015 (-25.00%)
HEI.A : 177.21 (-0.95%)
DAC : 90.26 (-2.27%)
MOMO : 5.81 (-1.36%)
CRM : 231.94 (+1.27%)
A : 129.85 (-0.55%)
HPQ : 35.51 (-2.58%)
COST : 855.67 (+1.15%)
DELL : 134.98 (-0.03%)
MRVL : 73.27 (+0.55%)
Stocks in play: Arch Biopartners Inc.

Announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics Committee ...

ARCH.VN : 1.690 (-1.17%)
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage...

ARCH.VN : 1.690 (-1.17%)
ACHFF : 1.2300 (-1.60%)
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...

ARCH.VN : 1.690 (-1.17%)
ACHFF : 1.2300 (-1.60%)
Shares for Interest Debt Settlement

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the...

ARCH.VN : 1.690 (-1.17%)
ACHFF : 1.2300 (-1.60%)
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...

ARCH.VN : 1.690 (-1.17%)
ACHFF : 1.2300 (-1.60%)
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Trial

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys which is common in moderate to severe...

ARCH.VN : 1.690 (-1.17%)
ACHFF : 1.2300 (-1.60%)
Unaware of Any Undisclosed Material Change

TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc....

ARCH.VN : 1.690 (-1.17%)
ACHFF : 1.2300 (-1.60%)
Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

ARCH.VN : 1.690 (-1.17%)
ACHFF : 1.2300 (-1.60%)
Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease

TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...

ARCH.VN : 1.690 (-1.17%)
ACHFF : 1.2300 (-1.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio...

See More

Key Turning Points

3rd Resistance Point 1.810
2nd Resistance Point 1.770
1st Resistance Point 1.730
Last Price 1.690
1st Support Level 1.650
2nd Support Level 1.610
3rd Support Level 1.570

See More

52-Week High 2.560
Fibonacci 61.8% 1.953
Fibonacci 50% 1.765
Last Price 1.690
Fibonacci 38.2% 1.577
52-Week Low 0.970

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar